Trader consensus heavily favors no new coronavirus pandemic in 2026, with the 90.3% implied probability reflecting sustained low SARS-CoV-2 circulation reported by WHO and CDC surveillance through mid-2026. Global test positivity rates hover near 1-2%, confirmed cases remain in the low thousands monthly, and the overall public health risk assessment stays moderate without evidence of a novel strain or variant driving exponential growth. High population immunity from prior infections and vaccination, combined with the absence of significant immune-escape variants achieving dominance, supports this positioning. Realistic challenges include undetected zoonotic spillovers or a highly divergent variant emerging with enhanced transmissibility, which ongoing genomic monitoring by agencies like WHO could flag through updated risk assessments.